We have located links that may give you full text access.
Journal Article
Research Support, Non-U.S. Gov't
Controlling Nutritional Status score: A new prognostic indicator for patients with oligometastatic prostate cancer.
Current Problems in Cancer 2019 October
The Controlling Nutritional Status (CONUT) score is associated with prognosis in a variety of cancers, but the association with prognosis in oligometastatic prostate cancer has not been reported. And the effect of the CONUT score on the prognosis of prostate cancer was not compared with the platelet to lymphocyte ratio (PLR) and the neutrophil to lymphocyte ratio (NLR). A total of 94 patients who underwent surgery for oligometastatic prostate cancer from January 2015 to December 2017 were retrospectively analyzed.The appropriate cut-off values of CONUT, PLR, and NLR were determined by X-tail. CONUT scores were statistically significant for Gleason scores, T-stage, tumor margin, NLR, and PLR (P < 0.05). We evaluated the effect of CONUT scores on PSA progression-free survival. Univariate and multivariate analyses were performed to determine the independent predictors of CONUT scores. On univariate analysis, CONUT scores, NLR, and PLR were significantly associated with PSA progression-free survival (P < 0.05). Multivariate analysis showed that the CONUT score was an independent prognostic factor (P < 0.05). The present study indicates that the CONUT score is an independent prognostic factor for patients with oligometastatic prostate cancer.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app